Drugs / HDM2017
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07274085 | Nov 2025 → Dec 2026 expected | cancer | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07621159 | Jul 2026 → Nov 2027 expected | colorectal cancer | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HDM2017 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07274085 ↗ |
| Route | Intravenous | “HDM2017 intravenous infusion” NCT07274085 ↗ |